Please try another search
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Jason J. Luke | - | 2021 | Member of Scientific Advisory Board |
Robert Ross | - | - | Director |
Paul J. Clancy | 61 | 2020 | Non-Employee Independent Chairman |
Anthony J. O’Donoghue | - | - | Member of Scientific Advisory Board |
Deborah Charych | 58 | - | Member of Scientific Advisory Board |
Christina Rossi | 46 | 2021 | Independent Director |
Yuan Xu | 55 | 2022 | Independent Director |
Daniel Curran | 55 | 2020 | Independent Director |
Kwok-Kin Wong | - | 2021 | Member of Scientific Advisory Board |
Andy Minn | - | 2021 | Member of Scientific Advisory Board |
Jason J. Luke | - | 2021 | Member of Scientific Advisory Board |
Robert W. Ross | 49 | 2022 | Independent Director |
Christopher A. Hunter | - | - | Member of Scientific Advisory Board |
Jamie Spangler | - | 2021 | Member of Scientific Advisory Board |
Sara M. Bonstein | 42 | 2021 | Independent Director |
Tomas J. Heyman | 67 | 2022 | Independent Director |
Rene Russo | 48 | 2019 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review